1 / 57

Anatomy-based MLC Field Optimization for the Treatment of Gynecologic Malignancies

Anatomy-based MLC Field Optimization for the Treatment of Gynecologic Malignancies. Myriam Bouchard M.D. Nadeau S, Germain I, Raymond P.E., Harel F, Beaulieu F, Beaulieu L, Roy R, Gingras L Dep. of radiation oncology of L’Hotel-Dieu de Quebec, QC, Canada

astro
Download Presentation

Anatomy-based MLC Field Optimization for the Treatment of Gynecologic Malignancies

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Anatomy-based MLC Field Optimization for the Treatment of Gynecologic Malignancies Myriam Bouchard M.D.Nadeau S, Germain I, Raymond P.E., Harel F, Beaulieu F, Beaulieu L, Roy R, Gingras L Dep. of radiation oncology of L’Hotel-Dieu de Quebec, QC, Canada Dep. of Physics, Physics Engineering and Optics, Laval University, Quebec, Canada

  2. IMRT for GYN malignancies • Mundt et al.(Chicago, 2000)Portelance et al.(St. Louis, 2001)Heron et al.(Pittsburgh, 2003)Lujan et al.(Chicago, 2003) D’Souza et al. (Houston, 2005) Adequate target coverage OARs sparing • Small bowel • Rectum • Bladder • Bone marrow Myriam Bouchard M.D.

  3. IMRT for GYN malignancies • Post-operative whole-pelvis radiotherapy • More bowel to spare, bowel replacing uterus • Less organ motion • Good clinical results with IMRT 1 • 36 patients, whole-pelvis IMRT • Median follow-up = 19,6 month • 13.9% less GI-GII toxicity 1 MUNDT et al. IJROBP, vol.56 #5 (2003) pp.1354-1360 Myriam Bouchard M.D.

  4. IMRT for GYN malignancies • Disadvantages of IMRT • Large number of segments and MU • Increased scattered dose • Dose calculation uncertainties • Higher potential impact of machine or patient positioning errors • Increased planning, treatment and quality assurance time • Higher impact of organ motion Myriam Bouchard M.D.

  5. BallistaA new inverse planning approach A dosimetric study Approved by the local institutional committee for medical ethics

  6. Objectives • Evaluate Ballista as an alternative • Between 4-field and IMRT • For post-operative whole-pelvis radiotherapy in gynecologic malignancies Myriam Bouchard M.D.

  7. Hypothesis • Same target coverage • Organs at risk (OARs) sparing • Better than 4-field • As good as IMRT ? • Treatment delivery advantages Myriam Bouchard M.D.

  8. Materials and methods • 10 patients • Endometrial or cervix malignancies • Post-operative external radiotherapy • 45 Gy / 25 fractions, whole-pelvis Myriam Bouchard M.D.

  9. Inverse planning Materials and methods For comparison purposes 4 plans created for each patient • Conventional 4-field • Enlarged 4-field • Results for OARs at same PTV coverage • IMRT • Ballista Myriam Bouchard M.D.

  10. Materials and methods Forward planning 4-field enlarged 4-field

  11. Materials and methods • Planning CTscan as usual • Conventional planning : • 4-field plans based on bony landmarks • Created before other plan conception • Enlarged 4-field • Aperture shaped to PTV Myriam Bouchard M.D.

  12. Materials and methods Inverse planning IMRT Ballista

  13. Vessels+ 5 mm ITV 1 cm CTV (ITV) • External iliac nodes • Internal iliac nodes • Obturator nodes • Presacral region • 1/2 superior vagina • Parameters Myriam Bouchard M.D.

  14. CTV / ITV Myriam Bouchard M.D.

  15. 3D CTV Myriam Bouchard M.D.

  16. PTV = CTV + 1 cm Myriam Bouchard M.D.

  17. OARs • Bowel (colon + small bowel) • Region at risk to find bowel = RAR-B • Rectum • Bladder • Bone marrow Myriam Bouchard M.D.

  18. Bowel / RAR-B Myriam Bouchard M.D.

  19. IMRT • Plans created with Pinnacle3 system • Step-and-shoot • 7 coplanar and equidistant 6 MV beams • 1 extraction • 10-12 intensity levels • Minimum field area = 4 cm2 Myriam Bouchard M.D.

  20. Ballista1 • Inverse planning system • Recently developed at L’Hotel-Dieu de Qc • Simultaneous optimization • Gantry, table and collimator angles • Wedge angle and beam weights • Intensity modulation • Anatomy-based MLC fields 1 BEAULIEU et al. Med.Phys.31, 1546-1557 (2004) Myriam Bouchard M.D.

  21. Anatomy-based fields Myriam Bouchard M.D.

  22. Number of fields • Gantry and table angle • optimization • Addition of sub- • anatomic structures Ballista Steps Result / conclusion Feasibility Selection of a fixed geometry (class solution) New treatment that is comparable to IMRT Myriam Bouchard M.D.

  23. Beam orientation for Ballista plans 9 beams 23 MV Myriam Bouchard M.D.

  24. Number of fields • Gantry and table angle • optimization • Addition of sub- • anatomic structures Ballista Steps Result / conclusion Feasibility Selection of a fixed geometry (class solution) New treatment that is comparable to IMRT Myriam Bouchard M.D.

  25. Sub-anatomic structures Myriam Bouchard M.D.

  26. Analysis For each plan (4) created for each patient (10) • DVH • PTV and OARs • Number of segments • Number of MU • Statistics : Student’s paired t-test Myriam Bouchard M.D.

  27. Results Target coverage

  28. 4-field Enlarged 4-field IMRT Ballista Myriam Bouchard M.D.

  29. 77% p =0.03 4-field Enlarged 4-field IMRT Ballista PTV coverage / homogeneity (Mean±SEM, n=10) Myriam Bouchard M.D.

  30. Results OARs sparing

  31. + 34.7 % 4-field Enlarged 4-field IMRT Ballista RAR-B 40 and 45 Gy (Mean±SEM, n=10) For the same PTV coverage Myriam Bouchard M.D.

  32. + 20.8 % 4-field Enlarged 4-field IMRT Ballista RAR-B (Mean±SEM, n=10) Ballista vs 4-field : V45 Gy, p < 0,001 Myriam Bouchard M.D.

  33. 4-field Enlarged 4-field IMRT Ballista (Mean±SEM, n=10) RAR-B (Mean±SEM, n=10) 45 Gy : p = 0.15 40 Gy : p < 0.001 (diff. = 61.4 cm3 or 9.9% ) Myriam Bouchard M.D.

  34. Rectum – mean V 45 Gy Myriam Bouchard M.D.

  35. Rectum – mean V 45 Gy Myriam Bouchard M.D.

  36. Bladder – mean V 45 Gy Myriam Bouchard M.D.

  37. Bladder – mean V 45 Gy Myriam Bouchard M.D.

  38. OARs V47.25 Gy Myriam Bouchard M.D.

  39. OARs V47.25 Gy Myriam Bouchard M.D.

  40. Enlarged 4-field 4-field IMRT Ballista (Mean±SEM, n=10) Bone marrow Enlarged 4-field vs Ballista : V40 Gy, p < 0,001 (forthe same PTV coverage) Myriam Bouchard M.D.

  41. 4-field Enlarged 4-f Volumeirradié Volume traité Irradiated volume Treated volume (Mean±SEM, n=10) V 50% and V 95% Myriam Bouchard M.D.

  42. Results Treatment delivery

  43. Number of segments (Mean±SEM, n=10) Myriam Bouchard M.D.

  44. 4-field Monitor Units (Mean±SEM, n=10) Number of MU Myriam Bouchard M.D.

  45. ± 1.4 Gy Calculated / delivered doses • Impact of leaf position errors Myriam Bouchard M.D.

  46. Discussion

  47. Dose constraint on OARs Priorities in our study • First priority on RAR-B • Bladder • Relative important weight given to it… • Organ motion +++ • Eventually replaced by small bowel • Bone marrow : when possible Myriam Bouchard M.D.

  48. OARs results • Bone marrow results • Worse compared to conventional planning • but PTV coverage not optimal • Similar gains IMRT vs Ballista Myriam Bouchard M.D.

  49. OARs results To enhance sparing… • Organ motion study necessary 2 • To limit as possible expansion for PTV • In our study, ITV/PTV limited sparing of rectum • Optimal patient immobilization • essential 2 AHAMAD et al. (MDACC). IJROBP 62 (4) p.1117-1124 (2005) Myriam Bouchard M.D.

  50. Advantages Ballistavs IMRT • Number of segments reduced by 75% • Number of MU reduced by 55% Result in  scattered radiation •  risk of second malignancies Myriam Bouchard M.D.

More Related